ReNeuron Group Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
RNUGF
- Investments
-
1
ReNeuron Group General Information
Description
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.
Contact Information
Website
www.reneuron.comCorporate Office
- Pencoed Business Park
- Pencoed
- Bridgend CF35 5HY
- Wales, United Kingdom
Corporate Office
- Pencoed Business Park
- Pencoed
- Bridgend CF35 5HY
- Wales, United Kingdom
ReNeuron Group Stock Performance
As of 27-Jun-2024, ReNeuron Group’s current market cap is $2.44M with 57.2M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.44M | 57.2M | 2.12K |
ReNeuron Group Financials Summary
As of 31-Mar-2025, ReNeuron Group has a trailing 12-month revenue of $1.08M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 |
|---|---|---|---|---|
| EV | (3,337) | (4,723) | ||
| Revenue | 1,082 | 1,082 | 1,775 | 638 |
| EBITDA | 1,104 | 1,104 | (4,056) | (7,854) |
| Net Income | (6,511) | |||
| Total Assets | 2,125 | 2,125 | 4,832 | 11,945 |
| Total Debt | 0 | 0 | 0 | 521 |
ReNeuron Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ReNeuron Group Comparisons
Industry
Financing
Details
ReNeuron Group Competitors (67)
One of ReNeuron Group’s 67 competitors is Faron Pharmaceuticals, a Corporation company based in Turku, Finland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Faron Pharmaceuticals | Corporation | Turku, Finland | ||||
| Alzinova | Corporation | Gothenburg, Sweden | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Amarantus BioScience Holdings | Formerly Accelerator/Incubator backed | New York, NY |
ReNeuron Group Patents
ReNeuron Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-1465493-A1 | Cultured and encapsulated pancreatic stem cells | Inactive | 21-Dec-2001 | ||
| EP-1465493-A4 | Cultured and encapsulated pancreatic stem cells | Inactive | 21-Dec-2001 | ||
| EP-1301589-A1 | Culturing pancreatic stem cells having a specified, intermediate stage of development | Inactive | 30-Jun-2000 | ||
| EP-1301589-A4 | Culturing pancreatic stem cells having a specified, intermediate stage of development | Inactive | 30-Jun-2000 | C12N5/0676 |
ReNeuron Group Signals
ReNeuron Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ReNeuron Group Acquisitions (1)
ReNeuron Group’s most recent deal was a Merger/Acquisition with AmCyte for . The deal was made on 27-Jul-2007.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AmCyte | 27-Jul-2007 | Merger/Acquisition | Drug Delivery |
ReNeuron Group ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
ReNeuron Group FAQs
-
When was ReNeuron Group founded?
ReNeuron Group was founded in 1997.
-
Where is ReNeuron Group headquartered?
ReNeuron Group is headquartered in Bridgend, United Kingdom.
-
What is the size of ReNeuron Group?
ReNeuron Group has 8 total employees.
-
What industry is ReNeuron Group in?
ReNeuron Group’s primary industry is Drug Discovery.
-
Is ReNeuron Group a private or public company?
ReNeuron Group is a Public company.
-
What is ReNeuron Group’s stock symbol?
The ticker symbol for ReNeuron Group is RNUGF.
-
What is the current market cap of ReNeuron Group?
The current market capitalization of ReNeuron Group is $2.44M.
-
What is ReNeuron Group’s current revenue?
The trailing twelve month revenue for ReNeuron Group is $1.08M.
-
Who are ReNeuron Group’s competitors?
Faron Pharmaceuticals, Alzinova, Mesoblast, Minerva Neurosciences, and Amarantus BioScience Holdings are some of the 67 competitors of ReNeuron Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process